Tuesday, July 28

Browsing: CYLD

Research

OTUD4 stabilizes CYLD and counteracts BCL3 K63-linked polyubiquitination to suppress melanoma progression

By NewsCancerJuly 28, 20260

Melanoma is a highly aggressive malignancy in which dysregulated ubiquitin-dependent signaling contributes to tumor progression. OTUD4 is frequently downregulated in…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

Low-fat dietary pattern and dietary advanced glycation end-products intake: a secondary analysis of the Women’s Health Initiative randomized trial

Johnson & Johnson Proposes $5.5 Billion Talc Settlement to End Marathon Legal Fight

Mechanism-of-Action Switching and Treatment Selection After Progression in CLL

Browsing: CYLD

OTUD4 stabilizes CYLD and counteracts BCL3 K63-linked polyubiquitination to suppress melanoma progression

Low-fat dietary pattern and dietary advanced glycation end-products intake: a secondary analysis of the Women’s Health Initiative randomized trial

Johnson & Johnson Proposes $5.5 Billion Talc Settlement to End Marathon Legal Fight

Mechanism-of-Action Switching and Treatment Selection After Progression in CLL

FDA staff reiterate concerns about Replimmune skin cancer treatment

Low-fat dietary pattern and dietary advanced glycation end-products intake: a secondary analysis of the Women’s Health Initiative randomized trial

Johnson & Johnson Proposes $5.5 Billion Talc Settlement to End Marathon Legal Fight

Mechanism-of-Action Switching and Treatment Selection After Progression in CLL

FDA staff reiterate concerns about Replimmune skin cancer treatment

Latest Post

Low-fat dietary pattern and dietary advanced glycation end-products intake: a secondary analysis of the Women’s Health Initiative randomized trial

Johnson & Johnson Proposes $5.5 Billion Talc Settlement to End Marathon Legal Fight

Mechanism-of-Action Switching and Treatment Selection After Progression in CLL

Subscribe to Updates

What's Hot

Browsing: CYLD